Furthermore, over the past decade, EpCAM has been rediscovered as a CSC marker in colon [20], breast [21], hepatocellular [22], and pancreatic cancers [23], which makes it a potential molecular target for novel cancer therapy. Here, EPCAM is linked to cancer.